NAV

Allogeneic natural killer cells

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Allogeneic natural killer cells
DrugBank Accession Number
DB18630
Background

Not Available

Type
Biotech
Groups
Investigational
Biologic Classification
Cell transplant therapies
Other cell transplant therapies
Synonyms
  • Allogeneic ex vivo-generated natural killer cells from CD34+ umbilical cord blood progenitor cells
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
oNKord (Glycostem Therapeutics B.V.)

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentHepatocellular Carcinoma1
2CompletedTreatmentMantle Cell Lymphoma (MCL) / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Indolent Adult Non-Hodgkin Lymphoma / Refractory Diffuse Large B Cell Lymphoma (DLBCL) / Refractory Follicular Lymphoma / Refractory Indolent Adult Non-Hodgkin Lymphoma1
2TerminatedTreatmentFallopian Tube Cancer / Ovarian Cancer / Peritoneal Cancer1
1RecruitingTreatmentRecurrent Cutaneous Melanoma / Recurrent Lip and Oral Cavity Carcinoma / Recurrent Malignant Endocrine Neoplasm / Recurrent Malignant Female Reproductive System Neoplasm / Recurrent Malignant Male Reproductive System Neoplasm / Recurrent Malignant Mesothelioma / Recurrent Malignant Neoplasm of Multiple Primary Sites / Recurrent Malignant Oral Neoplasm / Recurrent Malignant Pharyngeal Neoplasm / Recurrent Malignant Skin Neoplasm / Recurrent Malignant Soft Tissue Neoplasm / Recurrent Malignant Solid Neoplasm / Recurrent Malignant Thyroid Gland Neoplasm / Recurrent Malignant Urinary System Neoplasm / Refractory Cutaneous Melanoma / Refractory Malignant Bone Neoplasm / Refractory Malignant Endocrine Neoplasm / Refractory Malignant Female Reproductive System Neoplasm / Refractory Malignant Male Reproductive System Neoplasm / Refractory Malignant Mesothelioma / Refractory Malignant Neoplasm of Multiple Primary Sites / Refractory Malignant Oral Neoplasm / Refractory Malignant Pharyngeal Neoplasm / Refractory Malignant Skin Neoplasm / Refractory Malignant Soft Tissue Neoplasm / Refractory Malignant Solid Neoplasm / Refractory Malignant Thyroid Gland Neoplasm / Refractory Malignant Urinary System Neoplasm1
1RecruitingTreatmentRecurrent Gliosarcoma / Recurrent Supratentorial Glioblastoma / Supratentorial Gliosarcoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at October 04, 2023 17:28 / Updated at October 05, 2023 17:34